Safety of moxifloxacin and voriconazole in corneal storage media on porcine corneal endothelial cells

J Ocul Pharmacol Ther. 2010 Aug;26(4):315-8. doi: 10.1089/jop.2009.0136.

Abstract

Purpose: The aim of this study was to evaluate the safety of moxifloxacin and voriconazole as a supplement in corneal storage media for porcine corneal endothelial cells.

Methods: Twenty-eight eyes were divided into 4 groups. In the control group (the C group), corneal buttons were stored for 3 days in Optisol-GS. In the treatment group, the corneal buttons were preserved for 3 days in Optisol-GS mixed with 250 microg/mL moxifloxacin (M group), 100 microg/mL voriconazole (V group), and 250 microg/mL moxifloxacin plus 100 microg/mL voriconazole (MV group). We evaluated the samples via specular microscopy before and after 3 days of preservation. The mean changes of endothelial cell counts were compared among the 4 groups. Scanning electron microscopy was conducted after 3 days of preservation.

Results: Before the preservation, the endothelial cell counts did not differ among the 4 groups (P > 0.05). After 3 days of preservation, the endothelial cell count in the MV group was the lowest among the 4 groups (P < 0.05). After 3 days of preservation, the rate of corneal endothelial cell loss in the M and V groups did not differ significantly from the control group (P > 0.05). The rate of endothelial cell loss in the MV group was significantly higher than that of the control group (P < 0.05). Scanning electron microscopy revealed a normal mosaic pattern for the C, V, and F groups, but hexagonality was not preserved in the MV group.

Conclusion: Preservation in Optisol-GS mixed with moxifloxacin (250 microg/mL) plus voriconazole (100 microg/mL) induced significant toxicity on the endothelial cells in porcine corneas, when compared with the control group.

MeSH terms

  • Animals
  • Anti-Infective Agents / metabolism
  • Anti-Infective Agents / therapeutic use
  • Anti-Infective Agents / toxicity*
  • Aza Compounds / metabolism
  • Aza Compounds / therapeutic use
  • Aza Compounds / toxicity*
  • Cell Count
  • Cell Survival / drug effects
  • Chondroitin Sulfates*
  • Complex Mixtures
  • Cornea / drug effects
  • Cryopreservation
  • Culture Media, Serum-Free
  • Dextrans*
  • Endothelium, Corneal / cytology
  • Endothelium, Corneal / drug effects*
  • Fluoroquinolones
  • Gentamicins*
  • Moxifloxacin
  • Organ Preservation Solutions*
  • Pyrimidines / metabolism
  • Pyrimidines / therapeutic use
  • Pyrimidines / toxicity*
  • Quinolines / metabolism
  • Quinolines / therapeutic use
  • Quinolines / toxicity*
  • Swine
  • Tissue Preservation*
  • Triazoles / metabolism
  • Triazoles / therapeutic use
  • Triazoles / toxicity*
  • Voriconazole

Substances

  • Anti-Infective Agents
  • Aza Compounds
  • Complex Mixtures
  • Culture Media, Serum-Free
  • Dextrans
  • Fluoroquinolones
  • Gentamicins
  • Organ Preservation Solutions
  • Pyrimidines
  • Quinolines
  • Triazoles
  • Chondroitin Sulfates
  • Optisol
  • Voriconazole
  • Moxifloxacin